Management healthcare consultancy opens new offices in New York and London
The expansion will enable Putnam Associates to access the European market and to offer more localised support to its clients.
Putnam Associates, a US-based strategic management healthcare consultancy and part of UDG Healthcare, has recently opened two new offices in New York and London.
Headquartered in Boston with an office in San Francisco, Putnam employs more than 130 people and offers specialist consultancy services across the product life cycle to life science organisations with particular strengths in product commercialisation, market access strategy, and medical and scientific affairs.
The consultancy is opening new offices in Chiswick, London and in Midtown Manhattan, New York as part of its strategy to increase its global footprint and offer more localised support to its clients.
Putnam will also tap into the talent pools of both cities and plans to recruit experienced associates and management consultants across a number of roles in both locations.
Commenting on the new offices, Remco op den Kelder, CEO said: “Being part of UDG has created a number of opportunities for Putnam to leverage the infrastructure and resources of a global leader in life science services in a number of key regions.
“Our new office in London is a huge opportunity for us to access the European market.”
Putnam significantly strengthened the breadth of services offered by Ashfield’s Advisory division when it was acquired in early 2019. The consultancy added capabilities and scale to the existing advisory pillar, in particular in the global pricing, value and access area.
Op den Kelder continued: “Our new locations will also enable us to add to our talented teams as we look to recruit at every level, from senior leaders and experienced management consultants to graduates looking to start a career in the sector.
“The life sciences is an exciting industry to be a part of, the work we do is impactful and we work in a very dynamic environment so we’re always searching for top performers to join us.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance